← FDA DRUG APPROVALS

FDA ANDA · ANDA208741

DOXYCYCLINE HYCLATE

Sponsor: LUPIN

APPLICATION
ANDA208741
TYPE
ANDA
ORIGINAL APPROVAL
2023-08-11
LATEST ACTION
2023-08-11
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Discontinued

Products

DOXYCYCLINE HYCLATEDiscontinued
DOXYCYCLINE HYCLATE EQ 200MG BASE · TABLET, DELAYED RELEASE · ORAL
DOXYCYCLINE HYCLATEDiscontinued
DOXYCYCLINE HYCLATE EQ 120MG BASE · TABLET, DELAYED RELEASE · ORAL
DOXYCYCLINE HYCLATEDiscontinued
DOXYCYCLINE HYCLATE EQ 80MG BASE · TABLET, DELAYED RELEASE · ORAL
DOXYCYCLINE HYCLATEDiscontinued
DOXYCYCLINE HYCLATE EQ 60MG BASE · TABLET, DELAYED RELEASE · ORAL
DOXYCYCLINE HYCLATEDiscontinued
DOXYCYCLINE HYCLATE EQ 150MG BASE · TABLET, DELAYED RELEASE · ORAL
DOXYCYCLINE HYCLATEDiscontinued
DOXYCYCLINE HYCLATE EQ 100MG BASE · TABLET, DELAYED RELEASE · ORAL
DOXYCYCLINE HYCLATEDiscontinued
DOXYCYCLINE HYCLATE EQ 75MG BASE · TABLET, DELAYED RELEASE · ORAL
DOXYCYCLINE HYCLATEDiscontinued
DOXYCYCLINE HYCLATE EQ 50MG BASE · TABLET, DELAYED RELEASE · ORAL

Approval history

2023-08-11UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →